Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
← catalyst calendarNCT06005493 · readout in 330 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
280estimated
Sites
25
Countries
China, France, Japan +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-11 | actual | When the study began enrolling |
| Primary completion | 2027-07-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-16 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gastric Cancer
- Gastro-esophageal Junction Cancer
- Pancreatic Ductal Adenocarcinoma
- Esophageal Adenocarcinoma
Intervention
- Drug: AZD5863
Primary outcomes
what the primary-completion date above is the date OFThe number of patients with adverse events
measured From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy
The number of patients with adverse events of special interest
measured From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy
The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.
measured From first dose of study drug until the end of Cycle 1
The number of patients with serious adverse events
measured From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy
Objective Response Rate (ORR)
measured From first dose of study drug to progressive disease or death in the absence of disease progression (approx. 2 years)
Publications
- PMID 40759445 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed